InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Nayax direct listing
The shares are listed on the Nasdaq Global Select Market
Interra Acquisition HK$1 billion IPO
We advised the SPAC on its IPO and HKEX listing
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Tuya global offering and dual primary listing on the Hong Kong Stock Exchange
We advised Tuya Inc. on its HK$141 million global offering and dual primary listing on the HKEX
Financials Acquisition £150 million IPO
The shares are listed on the London Stock Exchange
Beike’s dual primary listing on the Hong Kong Stock Exchange
This is the first dual primary listing by way of introduction with WVR structure on the HKEX
Investcorp India Acquisition $258.8 million IPO
The SPAC offering consists of 25,875,000 units
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
RA Special Acquisition $230 million IPO
The SPAC IPO shares are listed on Euronext Amsterdam